Variant · Expression
ZNF217 Overexpression
CI-VAR-00003242Explore in graph →CIViC 5064
Curated evidence
Evidence by cancer (4 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22728437
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Breast Neoplasm2 | ||||||||
| ZNF217 Overexpression | (prognostic) | Prognostic | D | Supports Poor Outcome | 3 | submitted | EID12208ZNF217 overexpression is linked to reduced survival across multiple breast cancer subtypes. A meta-analysis of relapse-free survival across nine studies involving 858 patients revealed that higher ZNF… (full text at CIViC) PMID 22728437 · Littlepage et al., 2012 · Open in CIViC | civic |
| ZNF217 Overexpression | Triciribine | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12209Triciribine inhibits ZNF217-driven tumour growth and signalling both in vivo and in vitro. In mouse models, triciribine reduced tumour burden and levels of phospho-AKT and phospho-MAPK, while increasi… (full text at CIViC) PMID 22728437 · Littlepage et al., 2012 · Open in CIViC | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available